Literature DB >> 19002757

Tricuspid valve replacement and levosimendan.

Ferit Cicekcioglu1, Ali Ihsan Parlar, Levent Altinay, Kerem Yay, Salih Fehmi Katircioglu.   

Abstract

Isolated tricuspid valve replacement, which is not a common operation, is associated with poor short and long-term results, and the postoperative morbidity and mortality rates are high. The main reason for these adverse effects is the acute manifestation of chronic right heart failure. To treat right heart failure, we used levosimendan for its inotropic and vasodilatatory effects, and it does not increase the calcium overload in myocardial cells. We report two cases of tricuspid valve replacement operations performed using levosimendan. Both patients receiving levosimendan tolerated the operations well, and their postoperative courses were uneventful.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19002757     DOI: 10.1007/s11748-008-0298-8

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  10 in total

1.  Levosimendan in severe right ventricular failure following mitral valve replacement.

Authors:  Rex Joseph Morais
Journal:  J Cardiothorac Vasc Anesth       Date:  2005-12-15       Impact factor: 2.628

2.  Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.

Authors:  H Yokoshiki; Y Katsube; M Sunagawa; N Sperelakis
Journal:  Eur J Pharmacol       Date:  1997-08-27       Impact factor: 4.432

3.  Dear levosimendan, the right ventricle will thank you!

Authors:  Martin Westphal; Andrea Morelli; Hugo Van Aken
Journal:  Crit Care Med       Date:  2007-03       Impact factor: 7.598

Review 4.  Levosimendan, a new inotropic and vasodilator agent.

Authors:  Wolfgang G Toller; Christian Stranz
Journal:  Anesthesiology       Date:  2006-03       Impact factor: 7.892

5.  Long-term results of porcine bioprostheses in the tricuspid position.

Authors:  O Jegaden; M Perinetti; M Barthelet; C Vedrinne; F Delahaye; P Montagna; P H Mikaeloff
Journal:  Eur J Cardiothorac Surg       Date:  1992       Impact factor: 4.191

6.  Preconditioning effects of levosimendan in coronary artery bypass grafting--a pilot study.

Authors:  L Tritapepe; V De Santis; D Vitale; M Santulli; A Morelli; I Nofroni; P E Puddu; M Singer; P Pietropaoli
Journal:  Br J Anaesth       Date:  2006-04-04       Impact factor: 9.166

7.  Long-term outcomes of tricuspid valve replacement in the current era.

Authors:  Farzan Filsoufi; Ani C Anyanwu; Sacha P Salzberg; Tim Frankel; Lawrence H Cohn; David H Adams
Journal:  Ann Thorac Surg       Date:  2005-09       Impact factor: 4.330

8.  Outcome following isolated tricuspid valve replacement.

Authors:  A A Mangoni; T G DiSalvo; G J Vlahakes; C A Polanczyk; M A Fifer
Journal:  Eur J Cardiothorac Surg       Date:  2001-01       Impact factor: 4.191

9.  What to expect after tricuspid valve replacement? Long-term results.

Authors:  Zafer H Iscan; Kerem M Vural; Ilknur Bahar; Levent Mavioglu; Ahmet Saritas
Journal:  Eur J Cardiothorac Surg       Date:  2007-06-06       Impact factor: 4.191

10.  Tricuspid valve replacement. Fifteen years of experience with mechanical prostheses and bioprostheses.

Authors:  H E Scully; C S Armstrong
Journal:  J Thorac Cardiovasc Surg       Date:  1995-06       Impact factor: 5.209

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.